Plasma decorin predicts the presence of esophageal squamous cell carcinoma

International Journal of Cancer

Volumn 127, Issue 9, 2010, Pages 2138-2146

  Wu, I Chen ^a   Wu, Deng Chyang ^a   Huang, Chun Chi ^b   Lin, Hung Shun ^b   Chen, Yu Kuei ^c   Tsai, Hui Jen ^a,c   Lu, Chieh Yu ^a   Chou, Shah Hwa ^a   Chou, Yi Ping ^d   Li, Ling Hui ^e   Tai, Shu Yu ^a   Wu, Ming Tsang ^a,f,g  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

decorin; esophageal squamous cell carcinoma; osteopontin; plasma markers; receiver operator characteristic

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; ALCOHOL; ARGININE CARBOXYPEPTIDASE; CYCLIN DEPENDENT KINASE 1; DECORIN; ENDOTHELIN 2; FIBROBLAST GROWTH FACTOR 1; INITIATION FACTOR 3; LIM PROTEIN; ORIGIN RECOGNITION COMPLEX; OSTEONECTIN; OSTEOPONTIN; PROTEIN SH3; TRANSCRIPTION FACTOR RUNX2; PROTEOGLYCAN; SCLEROPROTEIN; TUMOR MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BETEL NUT; CANCER RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE; TAIWAN; TOBACCO; BLOOD; CASE CONTROL STUDY; DRINKING BEHAVIOR; ESOPHAGUS TUMOR; MIDDLE AGED; PROGNOSIS; SMOKING; SQUAMOUS CELL CARCINOMA;

ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; PROTEOGLYCANS; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 77956625406     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25239     Document Type: Article

References (34)

1. Vizcaino AP, Moreno V, Lambert R, Parkin DM,. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002; 99: 860 -8.
2. Cancer Registry Annual Report, National Department of Health, Taiwan, Republic of China 2006. Available at
3. Lee CH, Lee JM, Wu DC, Hsu HK, Kao EL, Huang HL, Wang TN, Huang MC, Wu MT,. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer 2005; 113: 475 -82.
4. De Vita F, Di Martino N, Orditura M, Cosenza A, Galizia G, Del Genio A, Catalano G,. Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: A phase II study. Chest 2002; 122: 1302 -8.
5. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, et al. Treatment outcomes of resected esophageal cancer. Ann Surg 2002; 236: 376 -84; discussion 84-5.
6. Lee JM, Wu MT, Lee YC, Yang SY, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee CJ, Chen CJ,. Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 2005; 11: 4749 -53.
7. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV,. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 1998; 101: 406 -12.
8. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G, Iozzo RV,. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 2000; 275: 32879 -87.
9. Li X, Pennisi A, Yaccoby S,. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008; 112: 159 -68.
10. Banerjee AG, Bhattacharyya I, Lydiatt WM, Vishwanatha JK,. Aberrant expression and localization of decorin in human oral dysplasia and squamous cell carcinoma. Cancer Res 2003; 63: 7769 -76.
11. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Iozzo RV,. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005; 24: 1104 -10.
12. Augoff K, Grabowski K, Rabczynski J, Kolondra A, Tabola R, Sikorski AF,. Expression of decorin in esophageal cancer in relation to the expression of 3 isoforms of transforming growth factor-beta (TGF-beta1, -beta2 and -beta3) and matrix metalloproteinase-2 activity. Cancer Invest 2009; 27: 443 -52.
13. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR,. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610 -23.
14. Oates AJ, Barraclough R, Rudland PS,. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997; 17: 1 -15.
15. Crawford HC, Matrisian LM, Liaw L,. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206 -15.
16. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ,. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184 -90.
17. Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T, Shimada Y,. An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2006; 12: 1308 -16.
18. Kita Y, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Owaki T, Ishigami S, Aikou T,. Expression of osteopontin in oesophageal squamous cell carcinoma. Br J Cancer 2006; 95: 634 -8.
19. Wu IC, Wu MT, Chou SH, Yang SF, Goan YG, Lee JM, Chou YP, Bair MJ, Wang TE, Chen A, Chang WH, Kuo FC, et al. Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 2008; 32: 1989 -95.
20. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M,. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 2005; 68: 285 -92.
21. Lee CH, Lee JM, Wu DC, Wu DC, Hsu HK, Kao EL, Huang HL, Wang TN, Huang MC, Wu MT,. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer 2005; 113: 475 -82.
22. Campo S, Campo GM, Avenoso A, D'Ascola A, Musolino C, Calabro L, Bellomo G, Quartarone E, Calatroni A,. Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukemia and long survival synthesize decorin. Biochimie 2006; 88: 1933 -9.
23. Oates AJ, Barraclough R, Rudland PS,. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumor model. Oncogene 1996; 13: 97 -104.
24. Sung V, Gilles C, Murray A, Clarke R, Aaron AD, Azumi N, Thompson EW,. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res 1998; 241: 273 -84.
25. Euer N, Schwirzke M, Evtimova V, Burtscher H, Jarsch M, Tarin D, Weidle UH,. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res 2002; 22: 733 -40.
26. Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S,. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 2002; 8: 61 -74.
27. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF,. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994; 54: 832 -7.
28. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF,. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605 -11.
29. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF,. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79: 502 -8.
30. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E,. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79: 127 -32.
31. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S,. Vascular endothelial growth factor and osteopontin in Stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999; 160: 1269 -73.
32. Evan GI, Vousden KH,. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342 -8.
33. Casson AG, Wilson SM, McCart JA, O'Malley FP, Ozcelik H, Tsao MS, Chambers AF,. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 1997; 72: 739 -45.
34. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ,. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 9: 59 -67.